Menu Search
Equities

Interpace Biosciences Inc

PF42:STU

Interpace Biosciences Inc

Actions
  • Price (EUR)2.38
  • Today's Change-0.04 / -1.65%
  • Shares traded0.00
  • 1 Year change+146.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Interpace Biosciences Inc grew revenues 26.31% from 31.84m to 40.21m while net income improved from a loss of 21.96m to a gain of 802.00k.
Gross margin60.46%
Net profit margin10.88%
Operating margin14.14%
Return on assets34.54%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at Interpace Biosciences Inc fell by 1.33m. However, the company earned 3.79m from its operations for a Cash Flow Margin of 9.42%. In addition the company used 87.00k on investing activities and also paid 5.03m in financing cash flows.
Cash flow per share1.16
Price/Cash flow per share2.29
Book value per share-2.53
Tangible book value per share-2.53
More ▼

Balance sheet in USDView more

Interpace Biosciences Inc uses little or no debt in its capital structure.
Current ratio0.5919
Quick ratio0.5269
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.